You are here
ARISAN THERAPEUTICS INC
UEI: PYRKTQPNVJZ8
# of Employees: 8
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Identification of novel broad-spectrum Dengue antivirals
Amount: $449,400.00DESCRIPTION (provided by applicant): Dengue is the most common mosquito-borne viral disease in the world with no approved therapeutic treatment or vaccine to help those exposed to the virus. World Hea ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Optimization of Arenavirus Antivirals
Amount: $1,800,000.00DESCRIPTION provided by applicant Seven distinct arenavirus species have been associated with arenaviral hemorrhagic fevers AVHF in humans with case fatality rates as high as Human infectio ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Synthesis and Characterization of Polymeric Antioxidant microparticles for the pr
Amount: $300,000.00DESCRIPTION (provided by applicant): Influenza A viruses are a major global health concern. Despite annual vaccination programs in the US, 10-15% of the population is infected annually accounting for ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
Identification of novel influenza antivirals
Amount: $473,362.00DESCRIPTION (provided by applicant): The influenza A virus represents one of the greatest global human health risks. Although vaccines provide significant protection from seasonal flu infections they ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Development of novel broad-spectrum influenza A inhibitors
Amount: $445,261.00DESCRIPTION (provided by applicant): The influenza A virus represents one of the greatest global human health risks. While vaccines provide significant protection from seasonal flu infections they sti ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health
